Jim Gabriele named president and CEO of M2GEN

Jim Gabriele was named president and chief executive officer of M2GEN.

Gabriele is a data scientist who was most recently senior vice president and chief strategy & data science officer within the Medical Devices Sector at Johnson & Johnson.

M2GEN has linked clinical and genomic databases and runs one of the largest observational research studies in cancer, which tracks patients throughout their lifetime, links longitudinal clinical data with molecular information, and enables a deeper understanding of a patient’s disease.

As senior vice president and chief strategy & data Science officer at Johnson & Johnson, he led global strategy development, pricing strategy, data science, data strategy, digital customer experience and business insights.

Prior to that, he held senior strategy and data science roles in the Johnson & Johnson Pharmaceutical organization.

Gabriele succeeds Helge Bastian.

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

White House

Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future

The Trump administration did exactly what it said it would do to disorient anyone involved in making policy or touched by it. The president and his crew have “flooded the zone”—the term and the image are theirs, as is the strategy of dropping a flurry of executive orders and memoranda that shake the foundations of the American system of government, raising questions of legality and constitutionality, and, above all, making it a challenge for anyone to see the entire picture and think strategically.

January 31, 2025

Vol.51 No.04

By Paul Goldberg

Capitol Hill

With a spotlight on vaccines, abortion, Medicaid and Medicare, RFK Jr. goes before the Senate
The MAHA nominee trumpets radical transparency, but offers little clarity on his new agenda

In two raucous back-to-back hearings on Jan. 29 and Jan. 30, anti-vaccine crusader Robert F. Kennedy Jr. was grilled by members of the United States Senate Finance Committee and the Health, Education, Labor, and Pensions Committee as the Trump administration seeks his confirmation as secretary of the Department of Health and Human Services.

January 31, 2025

Vol.51 No.04

By Claire Marie Porter

Guest Editorial

Our challenge: To find zen in chaos

This column is a love letter of sorts to our field, a recognition of all that we have accomplished and an acknowledgement that we need to find a path forward that supports and empowers the best of what it is to invest in cancer research.

January 31, 2025

Vol.51 No.04

By W. Kimryn Rathmell

Guest Editorial

Foundations acquire a critical new role as federal funding for cancer research falters

The fight against cancer is complex. It’s global. And it’s indisputably expensive.

January 31, 2025

Vol.51 No.04

By Ryan Schoenfeld and Raymond N. DuBois

Guest Editorial

Cancer research fuels life-saving work

Over the past century, groundbreaking cancer research in the U.S. has led to life-saving medical advances that benefit patients worldwide. Scientists often devote their lives to making discoveries, putting their scientific endeavors ahead of status, income, or lifestyle. Investigators work tirelessly, often seven days a week, to solve complex medical problems. These efforts often lead to game-changing outcomes that help us understand difficult medical challenges, advance technologies and develop new therapies.

January 31, 2025

Vol.51 No.04

By Ze’ev Ronai

NCI study: Prevention and screening saved more lives than treatment in five common cancer types over the past half-century

Over the last 45 years, prevention and screening interventions have made a greater contribution to averting cancer deaths than have improvements in treatment, according to a modeling study led by researchers at NCI.

January 31, 2025

Vol.51 No.04

By Yiqing Wang and Jacquelyn Cobb